Related references
Note: Only part of the references are listed.Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
P. Dongiovanni et al.
GUT (2010)
Kupffer Cells Promote Hepatic Steatosis Via Interleukin-1β-Dependent Suppression of Peroxisome Proliferator-Activated Receptor α Activity
Rinke Stienstra et al.
HEPATOLOGY (2010)
Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis
Amalia Gastaldelli et al.
HEPATOLOGY (2009)
Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: A study in monozygotic and dizygotic twins
Janne Makkonen et al.
JOURNAL OF HEPATOLOGY (2009)
The Kruppel-Like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease
Luca Miele et al.
GASTROENTEROLOGY (2008)
A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio
Shaohua Chen et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2008)
Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease
Naga Chalasani et al.
JOURNAL OF HEPATOLOGY (2008)
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo et al.
HEPATOLOGY (2007)
Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease
Varman T. Samuel et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Genetics of alcoholic liver disease and nonalcoholic fatty liver disease
Nimantha Mark Wilfred de Alwis et al.
SEMINARS IN LIVER DISEASE (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population
Giorgio Bedogni et al.
BMC GASTROENTEROLOGY (2006)
Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ with pre-diabetic phenotypes -: Meta-analysis of 57 studies on nondiabetic individuals
Anke Toenjes et al.
DIABETES CARE (2006)
α1-Antitrypsin mutations in NAFLD:: High prevalence and association with altered iron metabolism but not with liver damage
Luca Valenti et al.
HEPATOLOGY (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease
Anna Wieckowska et al.
HEPATOLOGY (2006)
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease
Giovanni Targher et al.
DIABETES CARE (2006)
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease
N Villanova et al.
HEPATOLOGY (2005)
Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD)
JN Song et al.
FASEB JOURNAL (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Peroxisome proliferator-activated receptor α gene variation influences age of onset and progression of type 2 diabetes
DM Flavell et al.
DIABETES (2005)
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
JD Browning et al.
HEPATOLOGY (2004)
The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity
R Buzzetti et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2004)
Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis
C Namikawa et al.
JOURNAL OF HEPATOLOGY (2004)
Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese
JB Dixon et al.
JOURNAL OF HEPATOLOGY (2003)
Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis
H Kim et al.
DIABETES (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini et al.
HEPATOLOGY (2003)
Updated definitions of healthy ranges for serum alanine aminotransferase levels
D Prati et al.
ANNALS OF INTERNAL MEDICINE (2002)
Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma
E Bugianesi et al.
GASTROENTEROLOGY (2002)
Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease
L Valenti et al.
GASTROENTEROLOGY (2002)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats -: Comparison with PPAR-γ activation
JM Ye et al.
DIABETES (2001)
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
D Altshuler et al.
NATURE GENETICS (2000)
Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity
M Guerre-Millo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes
K Hara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients
L Mussoni et al.
ATHEROSCLEROSIS (2000)
Prevalence of and risk factors for hepatic steatosis in northern Italy
S Bellentani et al.
ANNALS OF INTERNAL MEDICINE (2000)